SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
AtheroGenics, Inc.{AGIX}-nasdaq
An SI Board Since September 2000
Posts SubjectMarks Bans Symbol
332 21 0 AGIX
Emcee:  Secret_Agent_Man Type:  Unmoderated
Introduction Market Data Compact
AtheroGenics is developing
small-molecule drugs for the treatment
of such chronic inflammatory diseases
as atherosclerosis (clogging of the
arteries), asthma, and rheumatoid
arthritis. The company's products
prevent the production of inflammatory
proteins; its lead product, AGI-1067, is in
trials as a treatment for restenosis (the
reclosure of arteries after angioplasty).
AtheroGenics has identified other
compounds that may be used to treat
cystic fibrosis and organ transplant
rejection. Schering-Plough is helping to
develop AGI-1067. Founded in 1993 by
Emory University scientist Russell
Medford, AtheroGenics' investors
include William Blair & Company,
Alliance Technology Ventures, and
Sprout Group.

8995 Westside Pkwy.
Alpharetta, GA
30004 (Map)
Phone: 678-336-2500
Fax: 678-336-2501

atherogenics.com

atherogenics.com

AtheroGenics is an emerging pharmaceutical
company
focused on the discovery, development and
commercialization of novel drugs for the
treatment
of chronic inflammatory diseases, such as
atherosclerosis, asthma, and arthritis.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
332AtheroGenics files for Chapter 11 bankruptcy Tue Oct 7, 2008 7:52am EDT Oct 7 Doc Bones-10/7/2008
331One patient in the 150mg arm and two patients in the 75mg arm had <b> unexejgopher-7/31/2008
330AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical Trial of AGI-1sim1-7/31/2008
329<b>AtheroGenics drug shows promise in lowering sugar level</b> reutidos-4/14/2008
328It is being sold short nakedly. (sold without actual shares being settled.) So tStiltskin-2/3/2008
327Whats wrong with this stock ? What a clobbering . now 48 centstelebob-11/28/2007
326Mr. Clark: There is an interesting thread on the Yahoo CVTX board , subject: &qumlrb2113-11/27/2007
325siliconinvestor.comDewDiligence_on_SI-11/20/2007
324PS no commentary in the FDA guidance with regard to dose. My guess is that theyClarksterh-11/20/2007
323Courtesy of yourself - the updated FDA guidance on DILI: fda.gov Some key highClarksterh-11/20/2007
3228-K looks a little more sinister than that, I think: Consistent with our agreemmlrb2113-11/15/2007
321<i>I think we might've underestimated the FDA. It's unusual for itClarksterh-11/10/2007
320I think we might've underestimated the FDA. It's unusual for it to effecmlrb2113-11/10/2007
319THANK YOU MR. CLARK! Trial Discontinuing Highest Dose of AGI-1067 ANDES to Contimlrb2113-11/9/2007
318O.T. I see where our ol' friend the most honorable Mr. Marc Wohlbier (alwaysmlrb2113-11/4/2007
317<i>Doesn't seem fair that a drug should be penalized because it ran a Clarksterh-11/2/2007
316Thanks, Mr. Clark. I guess that's about all there is to talk about re. AGIX.mlrb2113-11/2/2007
315<i>Sorry. I didn't know we'd talked about bilirubin in statins<Clarksterh-11/1/2007
314<<And statin trials have NOT induced that (caveat: it is possible that themlrb2113-11/1/2007
313This Forbes article mentions 1067 in passing: forbes.comDewDiligence_on_SI-11/1/2007
312ml - <i>Rob Scott said the indications of liver toxicity were no worse thaClarksterh-11/1/2007
311Rob Scott said the indications of liver toxicity were no worse than in statins. mlrb2113-10/31/2007
310Yes. Thought I already acknowledged that. Thanks again.keokalani'nui-10/26/2007
309<i>It is only those drugs that cause hepatocellular injury extensive enougClarksterh-10/26/2007
308Draft Guidance for Industry on Drug Induced Liver Injury: fda.gov Excerpt: &lkeokalani'nui-10/25/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News